GlobeNewswire

Annual General Meeting of Infant Bacterial Therapeutics

Share

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among other things, the following was resolved:

  • adoption of the annual report
  • discharge from liability granted to board members and the Chief Executive Officer
  • that no dividend is given
  • that the board shall consist of six members without deputies
  • that remuneration should be paid to the Chairman of the Board of SEK 250,000 and an additional remuneration for the work as Chairman of the Board of SEK 400,000 and to other members of the company not employed by SEK 125,000 each. For members of the Remuneration Committee, a fee of forty thousand 40,000 is proposed to the Chairman and twenty thousand SEK 20,000 to each of the other members of the Committee
  • that the audit fee be paid according to approved invoice
  • re-election of Margareta Hagman, Eva Idén, Anthon Jahreskog, Kristina Sjöblom Nygren and Peter Rothschild and new election Robert Molander as board members
  • re-election of Peter Rothschild as Chairman of the Board
  • re-election of the registered accounting firm Deloitte AB
  • on the nomination committee in accordance with the nomination committee's proposal
  • guidelines for remuneration to senior executives in accordance with the Board's proposal, and
  • on the issue and transfer of warrants within the framework of an incentive program to employees of the company

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V.25.9.2020 20:00:00 CESTPress release

Amsterdam, September 25, 2020 Press Release HALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V. On September 25, 2020, Unibail-Rodamco-Westfield N.V. (“URW NV”) announced its 2020 half-year results and released its consolidated interim financial statements for the period ending June 30, 2020, which can be found on: https://www.urw-nv.com/en/investors/press-releases https://www.urw-nv.com/en/investors/press-releases and as an attachment to this press release. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield (“URW”). URW SE consolidates URW NV and its controlled undertakings, and its 2020 half-year results represent a comprehensive overview of URW, and is available on: https://www.urw.com/en/investors/financial-information/financial-results https://www.urw.com/en/investors/financial-information/financial-results For further information, please contact: Investor Relations Media Rela

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE ACTIVE  RHEUMATHOID  ARTHRITIS25.9.2020 19:00:00 CESTPress release

-- Jyseleca® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1 RA is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.2 Almost 3 million people in Europe are living with RA,3 many

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 17:10:39 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 576 SE00100498411.00 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 576 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 17:10:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 576 SE00100498411.00 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 576 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS25.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-10-01 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002023-12-01 578 SE00026959244.25 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-12-20193SE00110896221.00 %1,000 +/- 5002023-12-202312SE00111164741.00 %300 +/- 1502023-09-20516SE00091903901.25 %600 +/- 2502023-06-21144SE00111674281.00 %600 +/- 250 Settlement date 2020-10-05 Bids have to be entered by 10.00 on OCT 1, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 578 1,000 SEK million in issue 1587 1,000 SEK million in issue 193 300 SEK million in issue 2312 600 SEK million in issue 516 600 SEK million in issue 144 Maximum volume 5.5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON OCT 1, 2020. For more information, please con

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS25.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-09-29 Maturity dateLoanISIN codeCouponVolume, SEK million2022-06-012206SE00092694180.25 %1,100 +/- 2502023-11-132311SE00109482401.00 %1,100 +/- 2502025-05-12 2505 SE0011414010 1.00 % 1,100 +/- 250 2026-11-12 2611 SE0012569572 1.00 % 1,100 +/- 250 Maximum volume 4 310 million in total Settlement date 2020-10-01 Bids have to be entered by 11.00 on SEP 29, 2020 Highest permitted bid volume: 1 100 SEK million in issue 2206, 2311, 2505, and 2611. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON SEP 29, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se